Illumina (ILMN) and EraGen to Form Strategic Partnership
EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc. (NASDAQ: ILMN) today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.
Under these licensing agreements, EraGen Biosciences will have access to Illumina's BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen's MultiCode-PLx technology for the life sciences, research and clinical markets.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.72Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
